(MedPage Today) — FDA scientists said that investigational deramiocel, a stem cell treatment for Duchenne muscular dystrophy, did not meet its primary endpoint in a phase III trial, despite data presented at the American Academy of Neurology …
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
